Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study
Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia.
comments(0)
5-min edit window · permanent after that